Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human CXCL5 Anticorps:
anti-Rat (Rattus) CXCL5 Anticorps:
anti-Mouse (Murine) CXCL5 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Mouse (Murine) Polyclonal CXCL5 Primary Antibody pour IF (p), IHC (p) - ABIN741900
Heilmann, Schinke, Bindl, Wehner, Rapp, Haffner-Luntzer, Nemitz, Liedert, Amling, Ignatius: The Wnt serpentine receptor Frizzled-9 regulates new bone formation in fracture healing. dans PLoS ONE 2014
Show all 5 Pubmed References
Human Monoclonal CXCL5 Primary Antibody pour IHC (p), ELISA - ABIN562826
Zhou, Dai, Zhou, Wang, Yang, Wang, Huang, Fan, Zhou: Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. dans Hepatology (Baltimore, Md.) 2012
Show all 3 Pubmed References
Human Polyclonal CXCL5 Primary Antibody pour ELISA, WB - ABIN2473135
Strieter, Belperio, Phillips, Keane: CXC chemokines in angiogenesis of cancer. dans Seminars in cancer biology 2004
Human Monoclonal CXCL5 Primary Antibody pour CyTOF, ELISA (Capture) - ABIN4900299
Edwards, Johnson, Johnston: Combination therapy: Synergistic suppression of virus-induced chemokines in airway epithelial cells. dans American journal of respiratory cell and molecular biology 2006
study elucidates the important role of CXCL5 in the progression and prognosis of NSCLC. These findings suggested that CXCL5 might be a potential biomarker and novel therapeutic target for lung cancer
PERK (Montrer EIF2AK3 Anticorps)-p-eIF2alpha (Montrer EIF2A Anticorps) pathway could suppress metastasis in triple-negative breast cancer by inhibiting expression of PDL1 (Montrer CD274 Anticorps) and CXCL5 in tumor cells.
Mechanistically, AR modulated cytokine CXCL5 expression by altering AKT (Montrer AKT1 Anticorps) --> NF-kappaB (Montrer NFKB1 Anticorps) signaling, and interruption of AKT (Montrer AKT1 Anticorps) --> NF-kappaB (Montrer NFKB1 Anticorps) --> CXCL5 signaling using either specific inhibitors or siRNA suppressed AR-enhanced EC recruitment and AR-EC-promoted RCC (Montrer XRCC1 Anticorps) progression.
Curcumin suppressed CXCL5 expression by direct inhibition of IKKbeta (Montrer IKBKB Anticorps) phosphorylation, and inhibition of p38 MAPK (Montrer MAPK14 Anticorps) via induction of negative regulator MKP-1 (Montrer DUSP1 Anticorps).
The CXCL5 and the overexpression of miR (Montrer MLXIP Anticorps)-141 reduced levels of MMP-2 (Montrer MMP2 Anticorps) and MMP-9 (Montrer MMP9 Anticorps) in tumor necrosis factor-alpha (Montrer TNF Anticorps)-treated HT29 cells by means of repressing the inhibitory AKT (Montrer AKT1 Anticorps).
CXCL5 may promote mitomycin resistance by activating EMT (Montrer ITK Anticorps) and NF-kappaB (Montrer NFKB1 Anticorps) pathway. Thus, this study identifies CXCL5 as a novel chemoresistance-related marker in non-muscle invasive bladder cancer
findings for the first time provided evidence that ENA78 may play a key role of mediator in pathogenesis of Major Depressive Disorder(MDD) and in the mechanism of vinlafaxine effects on MDD.
Two haplotype blocks, one upstream to the coding region of UGT2A1 (rs146712414, P = 9.1 x 10(-5); odds ratio [OR], 1.34; 95% confidence interval [CI], 1.16-1.56) and one downstream of the genes PF4/PPBP/CXCL5 (rs1595009, P = 1.3 x 10(-4); OR, 1.32; 95% CI, 1.15-1.52), were associated with AgP.
our findings support CXCL5 as a promoter of colorectal cancer metastasis and a predictor of poor clinical outcomes in colorectal cancer patients.
CXCL5 levels were decreased in LSCC patient serum.
Identify Cxcl5 as a novel target of AHR (Montrer AHR Anticorps)-mediated gene expression in primary mouse keratinocytes.
Parenchymal polymorphonuclear myeloid-derived suppressor cell (PMN (Montrer TBCE Anticorps)-MDSC), have a positive correlation with IL1a (Montrer IL1A Anticorps), IL8 (Montrer IL8 Anticorps), CXCL5, and Mip-1a (Montrer CCL3 Anticorps), suggesting they may attract PMN (Montrer TBCE Anticorps)-MDSC into the tumor
These data identify suppression of CXCL2 (Montrer CXCL2 Anticorps) and CXCL5 chemoattractant expression by 11beta-HSD1 (Montrer HSD11B1 Anticorps) as a novel mechanism with potential for regulation of neutrophil recruitment to the injured myocardium, and cardiac fibroblasts as a key site for intracellular glucocorticoid regeneration during acute inflammation following myocardial injury.
IL-17RA (Montrer IL17RA Anticorps) regulates CXL-1 and 5 production in the lungs during the adaptive response.
STAT3 (Montrer STAT3 Anticorps) is required for maximal OSM (Montrer OSM Anticorps)-induced CXCL5 expression.
CXCL5 has a role in neutrophil recruitment in TH17-mediated glomerulonephritis
Since adaptive villus growth occurs despite impaired CXCL5 expression and enhanced angiogenesis, this suggests that the growth of new blood vessels is not needed for resection-induced mucosal surface area expansion following massive SBR (Montrer NXF1 Anticorps).
CXCL5 regulates pulmonary responses to infection and plays a central role in conferring clock control of inflammation.
findings demonstrated that CXCL1 (Montrer CXCL1 Anticorps) and CXCL5 are increased in circulation with onset of T2D, are produced by islets under stress, and synergistically affect islet function, suggesting that these chemokines participate in pathogenesis of T2D.
TLR2-induced epithelial-derived CXCL5 is critical for polymorphonuclear leukocyte-driven destructive inflammation in pulmonary tuberculosis.
The protein encoded by this gene is an inflammatory chemokine that belongs to the CXC chemokine family. This chemokine is produced concomitantly with interleukin-8 (IL8) in response to stimulation with either interleukin-1 (IL1) or tumor necrosis factor-alpha (TNFA). This chemokine is a potent chemotaxin involved in neutrophil activation.
C-X-C motif chemokine 5
, epithelial-derived neutrophil-activating protein 78
, neutrophil-activating peptide ENA-78
, neutrophil-activating protein 78
, small inducible cytokine subfamily B (Cys-X-Cys), member 5 (epithelial-derived neutrophil-activating peptide 78)
, CXC chemokine LIX
, chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2)
, cytokine LIX
, small-inducible cytokine B5
, C-X-C motif chemokine 6
, chemokine (C-X-C motif) ligand 5
, granulocyte chemotactic protein 2
, inducible cytokine subfamily B (Cys-X-Cys), member 6
, small-inducible cytokine B6
, granulocyte chemotactic protein-2
, small inducible cytokine B subfamily, member 5
, small inducible cytokine subfamily B, member 15